Conviction: 4/5 there may be near-term pullback for better entry at support General Thesis bounce from medium-term resistance (2017) although a bit of indecision around resistance line Weekly RSI showing good bounce near historical support Growth Margins high but declined in 2021 growth is low but around 50th percentile compared to self ...
AMGEN INC seems to be a solid buy for a +30% move to the upside within 12 month. So not a super exciting play. But never the less I'll share it with you. We had a productive EWT a-b-c like movement to the downside as a correction. We have bounced on the multi year (since 2017) support trendline (green) and should see another test of the ATH within next 12 months....
The PEAD projected a Bullish outlook for $AMGN after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 60%. If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
AMGN: Amgen Inc. 2021-12-01 16:00:00 Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis
Amgen Inc. discovers, develops, manufactures and delivers human therapeutics worldwide. It focuses on the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience. It has agreements with Novartis Pharma; Bayer HealthCar and Eli Lilly. Revenue TTM 25.4B Net Income TTM 5.7B EBITDA TTM 12.43B Net Margin TTM...
Hi Traders, AMGN fell after Q2 Earnings back in August and entered a downtrend down to ~200 USD. With this, it entered a strong area of support (ATH of 2018, low of Oct. 2020). AMGN then broke downward trend but then get capped by resistance at 210 USD and retestet downward trendline from above. By the end of October just before earnings it started to move up...
Amgen, Inc. (AMGN) Limit buy - 213,0$ Target - 243,05 Risk/Reward Ratio - 3,34 Stop-loss - 204,0 The price has approached a good level, we enter the position.
Interesting compare to the crash off in money supply velocity to Amgen’s delayed bull run Maybe something to do with their business model. Also compares to money supply and seems to correlate with increase in money supply dollars finding their new homes as we can see as the money supply velocity drops off drastically.
AMGEN INC in Weekly Timeframe Correction from November 2019 l....this correction expected to end in 6 month....only buy after breakout which is above 230 on a weekly Closing basis....after Breakout Stock expected to run for target 400-485
All trade in sell order/buy order, might not trigger, cancel if the price has run too far.
AMGN: Amgen 2021-09-25 20:00:00 FDA Approves Repatha® (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
I took a couple of months off to read a book i found on Amazon on Andrew Gann the inventor of GANN theory. After finishing his article i theorized that it could be transformed in these modern times. This will a Membership to perform, Alerts mean allot to people that want to automate the thought process behind this. Please note that i am not a paid person posting...
5th wave finished right at the major support, hoping for a jump if the support still valid. Previous batch of trades has closed except AMZN still running. (BABA-0.6%, UPS-1%, V-2%, AXP+1.5%, MAR+1.5%, SBUX+3%, WFC+0%)
NASDAQ:AMGN On a weekly timeframe chart, we can see that the candlesticks made a channel which have support line near 215 and the resistance near 260. We tasting support there.
AMGN - shares haven't had a weekly close below $216 in over a year. This is a key level, needs to hold. Weekly RSI is around 38.2. Shares bounced off this RSI level several times in the past.
Interesting graphical retracement for the Amgen stock which sees a considerable decline from the highs of the year. Where does the caution stem from? First, management highlighted that new patient prescriptions remain below pre-COVID-19 levels, and second, variants are suggesting demand may be muted for now. The stock has a solid capital appreciation potential and...
Formed nice base at this level. Good opportunity to accumulate for long term.